Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib

References

• RaabMSPodarKBreitkreutzIRichardsonPGAndersonKCMultiple myelomaLancet200937432433919541364
   PubMed Web of Science ®Google Scholar
• AugustsonBMBegumGDunnJAEarly mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 – Medical Research Council Adult Leukaemia Working PartyJ Clin Oncol2005239219922616275935
   PubMed Web of Science ®Google Scholar
• NucciMAnaissieEInfections in patients with multiple myeloma in the era of high-dose therapy and novel agentsClin Infect Dis2009491211122519769539
   PubMed Web of Science ®Google Scholar
• LonialSMitsiadesCSRichardsonPGTreatment options for relapsed and refractory multiple myelomaClin Cancer Res2011171264127721411442
   PubMed Web of Science ®Google Scholar
• LaubachJMitsiadesMCSMahindraAManagement of relapsed and relapsed/refractory multiple myelomaJ Natl Compr Canc Netw201191209121621975917
   PubMed Web of Science ®Google Scholar
• KumarSKRajkumarSVDispenzieriAImproved survival in multiple myeloma and the impact of novel therapiesBlood20081112516252017975015
   PubMed Web of Science ®Google Scholar
• PingaliSRHaddadRYSaadACurrent concepts of clinical management of multiple myelomaDis Mon20125819520722449368
   PubMed Web of Science ®Google Scholar
• RobinJFintelBPikovskayaODavidsonCCilleyJFlahertyJMultiple myeloma presenting with high-output heart failure and improving with anti-angiogenesis therapy: two case reports and a review of the literatureJ Med Case Rep2008222918627621
   PubMedGoogle Scholar
• ChowAWLeeCHHiwaseDKToLBHorvathNRelapsed multiple myeloma: who benefits from salvage autografts?Intern Med J20134315616122757772
   PubMed Web of Science ®Google Scholar
• Onyx Pharmaceuticals, IncKyprolis^® (carfilzomib) prescribing informationSouth San Francisco, CA, USAOnyx Pharmaceuticals, Inc.2012
   Google Scholar
• SiegelDSMartinTWangMA phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaBlood20121202817282522833546
   PubMed Web of Science ®Google Scholar
• SiegelDMartinTNookaAIntegrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase 2 clinical studiesHaematologica2013981753176123935022
   PubMed Web of Science ®Google Scholar
• JagannathSVijRStewartAKAn open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myelomaClin Lymphoma Myeloma Leuk20121231031823040437
   PubMed Web of Science ®Google Scholar
• VijRSiegelDSJagannathSAn open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomibBr J Haematol201215873974822845873
   PubMed Web of Science ®Google Scholar
• VijRWangMKaufmanJLAn open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myelomaBlood20121195661567022555973
   PubMed Web of Science ®Google Scholar
• BadrosAZVijRMartinTCarfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safetyLeukemia2013271707171423364621
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govPhase 2 study of carfilzomib in relapsed and refractory multiple myeloma Available from: http://clinicaltrials.gov/show/NCT00511238Accessed November 6, 2013
   Google Scholar
• ClinicalTrials.govPhase 2 study of carfilzomib in relapsed multiple myeloma Available from: http://clinicaltrials.gov/show/NCT00530816Accessed November 6, 2013
   Google Scholar
• ClinicalTrials.govStudy of the safety and pharmacokinetics of carfilzomib in subjects with relapsed and refractory multiple myeloma and varying degrees of renal function Available from: http://clinicaltrials.gov/show/NCT00721734Accessed November 6, 2013
   Google Scholar
• NookaABadrosAPatelPMcCullochLLonialSKaufmanJHematologic safety data from four phase 2 studies of single-agent carfilzomib in relapsed and/or refractory multiple myelomaAbstract (8086) and poster presented at the Annual Meeting of the American Society of Clinical OncologyJune 1–5, 2012Chicago, IL, USA
   Google Scholar
• Common Terminology Criteria for Adverse Events version 3.0Bethesda, MD, USAUS National Institute of Health, National Cancer Institute, Cancer Therapy Evaluation Program2006 Available from: http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_index.pdfAccessed March 12, 2014
   Google Scholar
• McBrideLSamuelCThe side effect profile of carfilzomib: from clinical trials to clinical practiceJ Adv Pract Oncol201342230
   Google Scholar
• RedicKCarfilzomib: a novel agent for multiple myelomaJ Pharm Pharmacol2013651095110623837578
   PubMed Web of Science ®Google Scholar
• SmithTJKhatcheressianJLymanGH2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guidelineJ Clin Oncol2006243187320516682719
   PubMed Web of Science ®Google Scholar
• AaproMSBohliusJCameronDA2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEur J Cancer20114783221095116
   PubMed Web of Science ®Google Scholar
• CrawfordJArmitageJBalducciLMyeloid growth factorsJ Natl Compr Canc Netw2013111266129024142827
   PubMed Web of Science ®Google Scholar
• ArmenianSHSunCLVaseTCardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular diseaseBlood20121204505451223034279
   PubMed Web of Science ®Google Scholar
• BakerKSNessKKSteinbergerJDiabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplantation Survivor studyBlood20071091765177217047152
   PubMed Web of Science ®Google Scholar
• KistlerKDRajangamKFaichGLanesSCardiac event rates in patients with newly diagnosed and relapsed multiple myeloma in US clinical practiceBlood2012120 Abstr 2916
   Web of Science ®Google Scholar
• YehETBickfordCLCardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and managementJ Am Coll Cardiol2009532231224719520246
   PubMed Web of Science ®Google Scholar
• LonialSNiesvizkyRMcCullochLRajangamKVijRCardiac and pulmonary safety profile of single-agent carfilzomib from four phase 2 studies in patients with relapsed and/or refractory multiple myelomaAbstract (4037) and poster presented at the Annual Meeting of the American Society of HematologyDecember 8–11, 2012Atlanta, GA, USA
   Google Scholar
• HarveyRLonialSWongAMcCullochLBadrosAKaufmanJRenal safety profile of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma from four phase 2 studiesAbstract and poster presented at Lymphoma and Myeloma CongressOctober 25–27, 2012New York, NY, USA
   Google Scholar
• MartinTVijRBadrosAZPatelPMcCullochLJagannathSCarfilzomib is associated with a low rate of typically mild to moderate, non-dose limiting treatment-emergent peripheral neuropathyAbstract 0857 and poster presented at Annual Meeting of the European Hematology AssociationJune 14–17, 2012Amsterdam, The Netherlands
   Google Scholar
• SezerOVesoleDHSinghalSBortezomib-induced tumor lysis syndrome in multiple myelomaClin Lymphoma Myeloma2006723323517229340
   PubMedGoogle Scholar
• HowardSCJonesDPPuiCHThe tumor lysis syndromeN Engl J Med20113641844185421561350
   PubMed Web of Science ®Google Scholar